Search results
Showing 46 to 60 of 66 results for parkinson
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
headache changes in appetite, and weight gain symptoms like those of Parkinson's disease. These may include slowness or difficulty...
Parkinson's disease with motor fluctuations: safinamide (ES6)
This evidence summary has been updated and replaced by NICE guideline NG71.
Parkinson's disease in over 20s: diagnosis and management (CG35)
This guidance has been updated and replaced by NICE guideline NG71.
Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)
This evidence summary has been updated and replaced by NICE guideline NG71.
Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)
This advice has been updated and replaced by NICE diagnostics guidance 51.
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
This evidence summary has been updated and replaced by NICE guideline NG71.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered.